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ABSTRACT  10 
The biocompatibility and cellular uptake of polymer, insulin polyelectrolyte complexes 11 
(PECs) prepared using polyallylamine-based polymers was evaluated in-vitro using Caco-2 12 
cell monolayers as a predictive model for human small intestinal epithelial cells.  13 
Poly(allyl amine) (PAA) and Quaternised PAA (QPAA) were thiolated using either 14 
carbodiimide mediated conjugation to N-acetylcysteine (NAC) or reaction with 2-15 
iminothiolane hydrochloride yielding their NAC and 4-thiobutylamidine (TBA) conjugates, 16 
respectively.  17 
The effect of polymer quaternisation and/or thiolation on the IC50 of PAA was determined by 18 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay carried out on 19 
Caco-2 cells (with and without a 24 h recovery period after samples were removed). Uptake 20 
of PECs by Caco-2 cells was monitored by microscopy using fluorescein isothiocyanate 21 
(FITC) labelled insulin and rhodamine-labelled polymers at polymer:insulin ratios (4:5) after 22 
0.5, 1, 2 and 4 h incubation in growth media (± calcium) and following pre-incubation with 23 
insulin.  24 
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MTT results indicated that quaternisation of PAA was associated with an improvement in 25 
IC50 values; cells treated with QPAA (0.001-4 mgmL-1) showed no signs of toxicity 26 
following a 24 h cell recovery period, while thiolation of QPAA resulted in a decrease in the 27 
IC50.   28 
Cellular uptake studies showed that within 2-4 h, QPAA and QPAA-TBA insulin PECs were 29 
taken up intracellularly, with PECs being localised within the perinuclear area of cells. 30 
Further investigation showed that uptake of PECs was unaffected when calcium-free media 31 
was used, while presaturating insulin receptors affected the uptake of QPAA, insulin PECs, 32 
but not QPAA-TBA PECs. 33 
The biocompatibility of PAA and uptake of insulin was improved by both thiol and 34 
quaternary substitution. 35 
 36 
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1. INTRODUCTION 49 
Oral delivery of insulin, used for the management of type 1 diabetes, could be referred to as 50 
one of the major long term goals of pharmaceutical research. Oral administration of insulin is, 51 
however, currently not feasible and exogenous insulin formulations are often given 52 
subcutaneously (Belchetz and Hammond, 2004). This is a constraint for the management of 53 
diabetes as the chronic nature of the condition requires regular injections. It is known that the 54 
regular injection regimen required for the management of diabetes predisposes diabetics to 55 
physiological stress due to multiple daily injections and has associated risk of infections 56 
and/or local reactions at injection sites as well as problems encountered during the insulin 57 
administration process such as precipitation of insulin in the injection pump (Wong, 2010). 58 
Parenteral administration of insulin also creates a significant difference in the normal 59 
physiological distribution of insulin in the body (Chen et al., 2011 and Ehud Arbit and 60 
Kidron, 2009) which may be associated with the occurrence of peripheral hyperinsulinaemia 61 
and insulin resistance resulting in hypoglycaemia, weight gain, neuropathy, retinopathy, 62 
atherosclerosis and hypertension in most diabetics (Ehud Arbit and Kidron, 2009).  63 
Oral delivery of insulin has the potential to eliminate these problems and offers an excellent 64 
alternative being the easiest and most convenient route of drug administration (Narayani, 65 
2001). Physiological distribution of orally administered insulin also mimics the natural 66 
physiological fate of insulin in the body, closely replicating the direct delivery of endogenous 67 
insulin to the liver (Satake et al., 2002). Oral insulin delivery is, however, mitigated by the 68 
susceptibility of insulin to proteolytic digestion in the gastrointestinal tract (GIT) as insulin is 69 
degraded by pepsin in gastric juice and proteases (carboxypeptidase, α-chymotrypsin and 70 
trypsin) in the intestinal lumen (Carino and Mathiowitz, 1999, Chen et al., 2011, Ehud Arbit 71 
and Kidron, 2009 and Wong, 2010).  Also, insulin a large, hydrophilic macromolecule with 72 
logP value < 0 exhibits poor permeation through the GIT epithelium unaided either 73 
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trancellularly or paracellularly. The presence of a layer of mucus above the intestinal mucosa 74 
also constitutes a further permeation barrier (Bendayan et al., 1994, Carino and Mathiowitz, 75 
1999 and Morishita and Peppas, 2006).  76 
Polyelectrolyte complexes (PECs) formed spontaneously by electrostatic interaction between 77 
oppositely charged polyelectrolytes have been found to have potential applications for the 78 
formulation of oral protein delivery systems. At physiologic pH, cationic polymers like 79 
chitosan and polyallylamine which feature protonable amine groups can undergo electrostatic 80 
complexation with negatively charged insulin forming PECs. These PECs are present in 81 
aqueous or buffer solutions as positively charged, spherical nanoparticles, with hydrodynamic 82 
sizes between 100-400 nm (Mao et al., 2005). Incorporating insulin intended for oral 83 
administration into particles of this size has been shown to enhance transcytotic uptake of 84 
insulin-loaded particles through Peyer’s patches (Lee, 1988, Rao and Ritschel, 1995 and Shah 85 
et al., 2002). The process of polyelectrolyte complexation also conveniently creates a 86 
platform where various functionalities that enhance oral insulin bioavailability can be 87 
imparted into the delivery system through rational modification of the carrier polymer 88 
structure. Also, the presence of a positive charge on these complexes may provide additional 89 
advantages like improved paracellular and transcellular transport of nanocomplexes as a 90 
result of electrostatic interaction with anionic components of epithelial cell tight junctions 91 
and cell membrane glycoproteins. Transmucosal transport is also facilitated by electrostatic 92 
interaction of PECs with anionic sulphate residues and sialic acid present in the intestinal 93 
mucosa (Lee, 1988, Rao and Ritschel, 1995 and Shah et al., 2002).  94 
Polymer quaternisation which stabilises and maximises cationic charge may, therefore, 95 
enhance processes like tight junction opening, insulin complexation and mucoadhesion that 96 
benefit from charge-based interactions. Quaternisation also improves the biocompatibility of 97 
polycationic polymers like PAA and polylysine which have been observed to be cytotoxic as 98 
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their free protonable amine groups have the ability to interact with anionic portions of 99 
glycoproteins on the cell membrane causing apoptosis (Slita et al., 2007). Quaternisation 100 
decreases the number of these protonable primary amine groups per molecule minimising 101 
toxicity (Brownlie et al., 2004). Other polymer modification processes like thiolation are 102 
directed at facilitating polymer-mucin interactions by introducing thiol-disulphide bonding 103 
between polymer and mucus thereby improving mucoadhesion of the dosage form. Thiolation 104 
has also been shown to reduce efflux of absorbed materials as well as limit some enzymatic 105 
degradation of proteins due to the chelating effect thiol groups can have (Lee, 1988, Rao and 106 
Ritschel, 1995 and Shah et al., 2002).  107 
A series of polyallylamine-based amphiphillic polymers (AP) consisting of PAA modified 108 
with hydrophobic pendant groups (palmitoyl, cetyl and cholesteryl groups) have been used 109 
previously in the formulation of PECs for oral insulin delivery (Thompson et al., 2008, 110 
Thompson et al., 2010 and Thompson et al., 2009). These AP were further modified by 111 
quaternisation. Complexation with negatively charged insulin was carried out in pH 7.4 Tris 112 
buffer resulting mostly in spherical nano-sized complexes. PECs prepared using palmitoyl 113 
grafted PAA (Pa)/QPAA (QPa) exhibited the best insulin loading efficiency and protection 114 
from peptic and tryptic degradation (Thompson et al., 2010 and Thompson et al., 2009). 115 
Palmitoyl grafted PAA showed 2-3 fold increase in IC50 value compared to PAA. The nature 116 
of the polymer used in PEC formulation was observed to play a vital role in determining the 117 
cellular uptake of the resultant complexes. Major factors that were found to affect the ability 118 
of the polymer to facilitate polymer-insulin PEC uptake include structural composition of the 119 
polymer, charge density, polymer conformation as well as hydrophilic/lipophilic balance 120 
(Fischer et al., 2003, Florence et al., 2000 and Malik et al., 2000). 121 
This study aims to further develop this work by modifying PAA to include one of two distinct 122 
thiol moieties (N-acetyl cysteine or 4-thiobutylamidine) as well as quaternary ammonium 123 
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moieties. The IC50 of these polymers against Caco-2 cells was ascertained using an MTT 124 
assay. These novel polymers were then complexed with insulin over a range of 125 
polymer:insulin ratios to ascertain their optimal mixing ratio by determination of 126 
complexation efficiency (using HPLC), size and zeta potential (using photon correlation 127 
spectroscopy) and %transmittance. Optimal ratio PECs were then used to treat a model gut 128 
epithelial cell line (Caco-2) to determine the effect of polymer architecture on PEC and 129 
polymer uptake (via fluorescence microscopy and fluorimetry, respectively). 130 
 131 
 132 
 133 
 134 
 135 
 136 
 137 
 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
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2. MATERIALS AND METHODS 148 
 149 
2.1. MATERIALS 150 
Poly(allylamine hydrochloride) (average Mw = 15 kDa), tris(hydroxymethyl)aminomethane 151 
(Tris base) (≥ 99%), N-(3-Dimethylaminopropyl)-N’-ethyl carbodiimide hydrochloride 152 
(EDAC), sodium hydroxide, N-hydroxysuccinimide (NHS), N-acetylcysteine, 2-153 
iminothiolane hydrochloride, sodium borohydride, iodine solution (0.5M), starch solution 154 
(2%), rhodamine B isothiocyanate (RBITC), fluorescein isothiocyanate (FITC)-insulin, 155 
Eagle’s minimum essential medium (EMEM), calcium-free EMEM, 3-(4,5-dimethylthiazol-156 
2-yl)-2,5-diphenyl tetrazolium bromide (MTT), Triton X-100, dimethylsulfoxide (DMSO) 157 
HPLC grade, Glycine, Dulbecco's phosphate buffered saline (PBS), sodium dodecyl sulphate 158 
(SDS) and trypan blue were from Sigma Aldrich, UK.  159 
Caco-2 cells were obtained from ECACC, Wiltshire UK and were used passage number 45-160 
70. L-glutamine (200 mM), non-essential amino acids, trypsin-EDTA (0.05 %) and DAPI 161 
were purchased from Invitrogen, Scotland. Foetal calf serum-activated (FCS) was obtained 162 
from Biosera, UK. All other reagents used were of analytical grade. 163 
 164 
2.2. POLYMER SYNTHESIS AND CHARACTERISATION  165 
 166 
2.2.1. Extraction of PAA base from hydrochloride and Quaternisation of PAA 167 
The methods used for the purification of the free PAA base from PAA hydrochloride and 168 
subsequent quaternisation of PAA to yield QPAA have been previously described in earlier 169 
reports published by our group (Narayani and Panduruanga Rao, 1995). The degree of 170 
quaternisation of the product was estimated by elemental analysis; samples (1 mg) were 171 
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analysed using a Perkin Elmer series 2 elemental analyser (Perkin Elmer, UK) and results 172 
were obtained in triplicate. 173 
 174 
2.2.2. Thiolation of PAA and QPAA  175 
Thiolation of PAA and QPAA by conjugation to N-acetylcysteine via an amide bond was 176 
carried out using a similar method to Yin et al. (Yin et al., 2009). N-acetylcysteine (250 mg; 177 
1.53 mmol) was dissolved in 100 ml of deionised water into which EDAC and NHS were 178 
added consecutively up to a final concentration of 200 mM each to activate the carboxylic 179 
acid groups of N-acetylcysteine. The mixture was adjusted to pH 4-5 using 2 M HCl and left 180 
stirring at room temperature for 1 h, after which PAA/QPAA (250 mg) was added into the 181 
reaction mixture and the pH of the mixture readjusted to between pH 4-5. The reaction was 182 
carried out under nitrogen at room temperature for 5 h without exposure to light. A control 183 
experiment containing equivalent concentrations of N-acetylcysteine and PAA without 184 
EDAC/NHS was also set up in the same way and allowed to run simultaneously. 185 
The thiolation of PAA and QPAA using amidine linkages was carried out as described 186 
previously (Bernkop-Schnürch et al., 2003). Briefly, PAA/QPAA (500 mg) was dissolved in 187 
50 ml deionised water and the pH adjusted to 6.5 using 5 M HCl. 2-iminothiolane 188 
hydrochloride (400 mg) was added into the flask, and the reaction left stirring under nitrogen. 189 
The experiment was conducted at room temperature in the dark for 14 h. 190 
The reaction mixtures for the thiolation experiments were dialysed (molecular weight cut-off 191 
– 7 kDa) in the dark at 4 °C, once against 5 L of 5 mM HCl, twice against 5 L of 5 mM HCl 192 
containing 1 % NaCl, once again against 5 L of 5 M HCl and finally against 5 L of 0.4 mM 193 
HCl. The various polymer conjugates isolated by dialysis were then freeze dried over 48 h 194 
using a VirTis adVantage freeze drier (Biopharma Process Systems, UK), characterised and 195 
stored at -20 °C. 196 
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2.2.3. Determination of free thiol and disulphide content 197 
The amount of free thiol groups immobilised on each thiolated conjugate was estimated by 198 
iodometric titration using a 1 % starch solution as an indicator. Each thiomer (10 mg) was 199 
dissolved in 1 ml of deionised water acidified with a drop of 2 M HCl. 1 % starch indicator 200 
(300 µl) was added into the polymer solution before titrating the solution with a 1 mM iodine 201 
solution until a permanent blue colour characteristic of the iodine-starch complex was 202 
observed (Vigl et al., 2009). The amount of thiol groups in mols per gram of polymer was 203 
estimated from a calibration plot prepared from titrating iodine against increasing 204 
concentrations (2-100 mgml-1) of an N-acetylcysteine reference standard (n=3; R2= 0.99).   205 
The total amount of thiol substituents (free and oxidised) immobilised on a gram of each 206 
polymer was obtained by reducing disulphide bonds (formed during thiolation) with sodium 207 
borohydride (NaBH4) to free thiols. Briefly, a 1 ml solution (1 mgml-1) of each thiomer in pH 208 
7.4 Tris buffer was prepared in a glass vial and mixed with 4 % sodium borohydride solution 209 
(2 ml) and incubated at 37 °C for 1 h in a shaking water bath. The reaction was then stopped 210 
by slowly adding 400 µl of 5 M HCl with gentle stirring. Each reaction mixture obtained was 211 
immediately subjected to iodometric titration as described above to obtain free thiol content. 212 
The disulphide bond content of each thiomer was estimated by subtracting the free thiol 213 
content obtained for each polymer prior to the reduction process from the total thiol content 214 
which was obtained after treatment with the reducing agent. Experiments were carried out in 215 
triplicate. 216 
 217 
2.2.4. Zeta potential  218 
The zeta potential (mV) of 1 mgml-1 polymer solutions in Tris buffer pH 7.4 contained in 219 
folded capillary cells was determined at 25°C by photon correlation spectroscopy (PCS) 220 
(Zetasizer Nano-ZS, Malvern Instruments, UK) (Thompson et al., 2009). 221 
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2.3. IN-VITRO POLYMER BIOCOMPATIBILITY TESTING 222 
The IC50 value of each test polymer was determined by MTT assay (Mosmann, 1983). Caco-223 
2 cells grown in supplemented EMEM (containing 10 % (v/v) FCS, 1 % (v/v) non-essential 224 
amino acids and 1 % (v/v) L-glutamine) at 37 °C, 5 % CO2 and 95 % humidity were used to 225 
seed 96-well plates at a cell density of 10,000 cells/200 µl of cell suspension per well. The 226 
cells were grown for 72 h, after which the culture media was aspirated and replaced with 200 227 
µl of polymer solutions (concentrations ranging between 0.001-0.5 mgml-1) prepared in 228 
supplemented EMEM without FCS (to avoid interaction of polymers with FCS). Positive and 229 
negative control wells were prepared by treating cells with 200µl of EMEM (without FCS) 230 
and 1 % Triton-X (in PBS), respectively. 231 
The plate was incubated for 24 h at 37 °C, 5 % CO2 and 95 % humidity, after which 50 µl of 232 
MTT (5 mgml-1 in PBS) was added into each well. The plate was subsequently wrapped in tin 233 
foil (to protect it from light) and incubated for 4 h.  The plate contents were subsequently 234 
aspirated and each well was then filled with DMSO (200 µl) followed by 25 µl of glycine 235 
buffer (7.5 gL-1 glycine, 5.9 gL-1 NaCl, pH 10.5). The plate was analysed by UV 236 
spectrophotometry (SoftMax Pro 5.0, Molecular Devices, U.S.A.) at 570 nm and cell viability 237 
(%) was calculated relative to the negative (cells treated with Triton-X in PBS) and positive 238 
(untreated cells in EMEM) controls (Thompson et al., 2009). The MTT assay was repeated 239 
for each polymer using cells allowed a 24 h recovery period in fresh supplemented culture 240 
media (with FCS) post-treatment with polymer solutions. Plots of % cell viability against 241 
polymer concentration were used to determine the IC50 value of the different polymers 242 
with/without a recovery period. 243 
 244 
 245 
 246 
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2.4. CELLULAR UPTAKE STUDIES 247 
 248 
2.4.1. Preparation of RBITC-labelled polymers and fluorescent polymer, insulin PECs 249 
For non-thiolated polymers, PAA and QPAA, 5 ml of RBITC in DMSO (1 mgml-1) was 250 
added dropwise over 10 min into 95 ml of a 0.05 % (w/v) solution of polymer in double-251 
distilled water with gentle magnetic stirring. The stirring was continued for one h and the 252 
mixture dialysed (molecular weight cut-off – 7 kDa; Medicell UK) against 5 L of double-253 
distilled water for 48 h with 6 water changes every 24 h (Lin et al., 2008). 254 
For thiolated polymers, methanol was used instead of DMSO to dissolve RBITC and the pH 255 
of the reaction kept at pH 4-5 using 5 M HCl to limit oxidation of thiol groups to disulphides 256 
(Ma et al., 2008). The reaction was also carried out under nitrogen and the mixture dialysed 257 
in the dark (MW cutoff-7 kDa; Medicell UK) against 5 L of 5 mM HCl for 24 h and then 5 L 258 
of 0.4 mM HCl for a further 24 h (6 changes every 24 h). 259 
The polymer solution obtained from the dialysis process was freeze dried over 48 h to yield a 260 
deep pink to purple solid.  261 
RBITC-tagged polymers were used in preparing fluorescent polymer, insulin nanocomplexes 262 
by mixing RBITC-labelled polymer with FITC-insulin at polymer:insulin (P: I) mass ratios of 263 
4:5 (0.2:0.25 mgml-1) in Tris buffer pH 7.4. This mass ratio was arrived at by polymer-insulin 264 
complexation optimisation experiments based on complexation efficiency, hydrodynamic 265 
diameter and %Transmittance values observed over a 48 h time course (data not shown). 266 
 267 
2.4.2. Monitoring cellular uptake of PECs by fluorescence microscopy 268 
Caco-2 cells were seeded at a density of 1 X 105 cellsml-1 in 24 well plates and grown over 3 269 
days at 5 % CO2, 95 % humidity and 37 °C (Thompson et al., 2011). The media contained in 270 
the wells was aspirated and washed with PBS.  Fluorescent complexes were prepared in pH 271 
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7.4 Tris buffer by mixing RBITC-labelled polymer with FITC-insulin at mass ratios of 4:5 272 
(0.2:0.25 mgml-1). These complexes were then diluted in FCS-free media to obtain 273 
concentrations of 0.005:0063 and 0.016:0.020 mgml-1 for non-quaternised and quaternised 274 
polymer complexes, respectively. The PEC concentrations used for the uptake experiments 275 
were based on the IC50 values of each polymer obtained from MTT assays conducted without 276 
a recovery period. Wells were treated with PECs and incubated for time periods of 0.5, 1, 2 277 
or 4 h. PEC uptake experiments were also carried out after reducing the concentration of 278 
quaternised polymers used to that of non-quaternised polymers (0.005:0063 mgml-1) to 279 
enable detection of concentration-based differences in uptake profile.  280 
After incubation PECs were removed and the cell layer subsequently washed (x2) with PBS 281 
and stained with 18.8 µgml-1 solution of DAPI in PBS for 10 min to highlight the nuclear 282 
region of the cells (Tyrer et al., 2002).  The wells were then washed (x2) with PBS and 283 
treated with trypan blue to highlight non-viable cells. Uptake of complexes was assessed by 284 
examining cells using a fluorescence microscope (Leica DMI4000B, Leica Microsystems 285 
Ltd. UK) (x20 objective lens). Images were captured on a camera fitted to the microscope 286 
and are indicative of replicate wells (n=3). Uptake of control, polymer only, solutions at the 287 
same concentrations and time intervals was also assessed by fluorescence microscopy. 288 
 289 
2.4.3. Quantification of polymer uptake  290 
Caco-2 cells were cultured and treated with RBITC-labelled polymers (PAA, QPAA, QPAA-291 
NAC and QPAA-TBA) using concentrations equivalent to that used in earlier uptake 292 
experiments over 2 h. The cell layer was then washed (x 3) with PBS and the cell layer 293 
attached to each well treated with 1 ml of 2 % SDS in PBS solution for 30 min to lyse cells 294 
(Yin et al., 2009).  The fluorescence intensity of the cell lysate obtained from the above 295 
procedure was measured by fluorescence spectrophotometer (Perkin Elmer LS55 296 
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Fluorescence Spectrophotometer, Perkin-Elmer, UK) using a 1 ml quartz cuvette and 297 
excitation/emission wavelength set at 547/590 nm for RBITC. The results obtained were 298 
input into calibration curves (n=3; R2 = 0.99) prepared using dilutions of the tagged polymers 299 
in 2 % SDS (concentrations ranging from 0.3-10 µgml-1). The values obtained were 300 
subsequently used to estimate the percentage of tagged polymer taken up by the Caco-2 cells.  301 
 302 
2.4.4. Investigation of PEC uptake mechanism  303 
Uptake experiments similar to that described in 2.4.2 were carried out after incubating cells in 304 
calcium-free EMEM (FCS-free) for 2 h prior to treatment with PECs to inhibit calcium-305 
dependent uptake mechanisms. Separate uptake experiments were also carried out using cell 306 
monolayers pre-incubated with 3 µgml-1 of free insulin for 1 h prior to polymer treatment to 307 
inhibit insulin-receptor mediated uptake mechanisms. Cell layers from these experiments 308 
were visualised under the fluorescence microscope and the results compared with that 309 
obtained from previous uptake experiments detailed in section 2.4.2. (Thompson et al., 2011) 310 
 311 
2.5. STATISTICAL ANALYSIS 312 
One-way ANOVA was used to analyse the effect of the respective polymers on cell viability 313 
using Tamhane T2 post-hoc test.  The level of significance is represented as p<0.05 *: 314 
p<;0.01 ** or p<0.001 ***. 315 
 316 
 317 
 318 
 319 
3.  320 
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3. RESULTS AND DISCUSSION 321 
 322 
3.1. POLYMER SYNTHESIS AND CHARACTERISATION 323 
After lyophilisation, all polymer conjugates appeared as white powders of fibrous structure 324 
which were readily soluble in aqueous media.  325 
The average degree of quaternisation of QPAA as estimated by elemental analysis was found 326 
to be 72 ± 2 mol% (mean ± S.D; n=3) at an average yield of 76.2 ± 5% (mean ± S.D; n=3).  327 
The  percentage yield (mean ± S.D; n=3) of PAA-NAC, QPAA-NAC, PAA-TBA and 328 
QPAA-TBA conjugates was found to be 68.8 ± 2.8 %, 73.6 ± 2.3 %, 73.1 ± 4.4 %  and 83.6 ± 329 
7.7 %, respectively.  330 
Immobilisation of reactive thiol groups on primary amino groups on the PAA/QPAA 331 
backbone was carried out using two types of covalent bonds. PAA and QPAA were coupled 332 
via a stable amide bond to N-acetylcysteine using a water-soluble carbodiimide cross-linker 333 
(EDAC) and NHS to form PAA/QPAA-N-acetylcysteine conjugates as shown in figure 1.  334 
PAA and QPAA were also coupled to 4-thiobutylamidine via a reaction with 2-iminothiolane 335 
hydrochloride, a thiol-containing imidoester forming PAA/QPAA-4-thiobutylamidine 336 
conjugates. These TBA conjugates have a protonated amidine bond which bears an extra 337 
positive charge on the thiol constituent at pH 7.4 (Albrecht K, Bernkop-Schnürch, 2007 and 338 
Bacalocostantis et al., 2012) as can be seen in figure 2.                                      339 
Optimisation of the coupling reaction between the polymers and N-acetylcysteine 340 
necessitated the inclusion of NHS in the cross-linking reaction to stabilise the O-acylisourea 341 
intermediate product of the EDAC-carboxylic acid reaction which is susceptible to hydrolysis 342 
and consequently has a short life span in aqueous media (Damink et al., 1996). The reaction 343 
was also carried out under nitrogen and at pH 4.5 to minimise oxidation of thiol groups to the 344 
reactive thiolate anion resulting in the formation of intramolecular disulphide bond formation 345 
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(Bernkop-Schnürch et al., 2004). An N-acylated amino acid was used during the reaction to 346 
prevent the occurrence of unwanted side reactions resulting in the formation of oligo/poly 347 
cysteine conjugates (Vigl et al., 2009). The zeta potential, total sulphydryl group content of 348 
each conjugate as well as the amount available as free thiols (SH) and disulphide (S-S) bonds 349 
are shown in table 1. 350 
A negligible amount of thiol groups (0.2 ± 0.06 µmolg-1 polymer) were detected in control 351 
samples obtained from similar NAC conjugation experiments carried out without the addition 352 
of EDAC/NHS. Results shown in table 1 indicate that the surface charge of the polymers 353 
varied with the nature of the substituting group. Quaternisation enhanced the cationic charge 354 
of PAA. Thiolation using 2-iminothiolane resulted in further increases of cationic charge of 355 
both parent polymers (PAA and QPAA) while conjugation of PAA/QPAA to NAC resulted 356 
in a reduction of cationic surface charge. This difference is probably related to the 357 
substitution of protonable primary amine groups with the uncharged amide bond present in 358 
NAC-based thiomers while the cationic substructure of the amidine group (figures 1 and 2) 359 
facilitates the retention of cationic charge in TBA-based thiomers. The marked variation in 360 
the surface charge of the thiomers obtained could have significant implications on the 361 
capacity of the polymer to complex with insulin as well as its ability to promote processes 362 
like tight junction opening and mucoadhesion that benefit from charge-based interactions. 363 
Polymer surface charge could also influence the biodistribution and cellular uptake of insulin 364 
PECs formed from the polymers (He et al., 2010 and Kotzé et al., 1997). 365 
 366 
3.2. BIOCOMPATIBILITY TESTING 367 
The toxicity profile of polymers was initially evaluated without the inclusion of a cell 368 
recovery period. Results from MTT assays conducted without a recovery period (WOR) were 369 
expressed as plots of % cell viability versus log polymer concentrations shown in figure 3. 370 
Available online 27 December 2014 – International Journal of Pharmaceutics 
IC50 values of each polymer obtained from MTT assays conducted without a recovery period 371 
are highlighted in table 2. 372 
The unmodified PAA backbone showed the highest toxicity having the lowest IC50 value of 373 
0.009 ± 0.003 mgml-1. This is expected as polycationic polymers like PAA and polylysine 374 
have been observed to be cytotoxic due to the availability of free protonable amine groups 375 
which have the ability to interact with anionic portions of glycoproteins on the cell membrane 376 
causing apoptosis (Slita et al., 2007). Quaternisation decreases the number of these 377 
protonable primary amine groups per molecule improving biocompatibility (Brownlie et al., 378 
2004), as may be seen by the marked improvement in IC50 exhibited by QPAA when 379 
compared to the non-quaternised PAA backbone (tables 2 and 3). This is consistent with the 380 
results obtained from other research groups where quaternisation of other polycations was 381 
observed to be associated with improvements in their toxicity profile (Bernkop-Schnürch et 382 
al., 2003).  383 
Thiol substitution of the PAA backbone was also observed to result in an increase in IC50 384 
values (smaller than was obtained with quaternisation) with PAA-NAC displaying a lower 385 
IC50 value than PAA-TBA (tables 2 and 3). This could be as a result of the lower level of 386 
primary amine substitution found in PAA-NAC (total thiol substitution-340 ± 4.1 µmol 387 
compared to 1080 ± 28 µmol thiol groups found in PAA-TBA) implying that PAA-NAC has 388 
a higher level of free protonable primary amine groups to exert cytotoxic effects.  389 
Thiolation of QPAA resulted in a reduction of IC50 suggesting that the thiol moieties had a 390 
negative effect on biocompatibility of the quaternised PAA backbone.  Thiols are capable of 391 
covalent interactions (thiol-disulphide reactions) with glycoproteins and can consequently 392 
damage protein components of cells irreversibly altering their structure/conformation (Wang 393 
et al., 2004). Quaternisation increased the IC50 of PAA-NAC, but had no noticeable effect on 394 
the IC50 of PAA-TBA. QPAA-TBA had the highest level of total substitution (thiol and 395 
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quaternary substitution combined) of primary amine groups and was therefore expected to 396 
have the highest IC50 of all polymers tested. It was therefore surprising that PAA-TBA and 397 
QPAA-TBA have approximately the same IC50 (0.02 mgml-1) (tables 2 and 3). This implies 398 
that the reduction in cytotoxic effects mediated by the quaternary groups present in QPAA-399 
TBA appear to have been completely mitigated by TBA-based thiol substitution, thereby 400 
suggesting that the TBA thiol moiety may have toxic effects on cells. This also highlights the 401 
fact that while quaternisation tends to completely mask the highly charged primary amine 402 
groups of PAA limiting their ability to damage cells, thiolation may only result in the 403 
replacement of one type of reactive groups (in this case free primary amine groups) with 404 
another type (thiol groups). The cationic substructure of the amidine linkage also makes it 405 
possible for these thiomers to initiate toxic effects associated with cationic charge as well as 406 
effects arising from the actual thiol group as mentioned earlier, making these TBA conjugates 407 
more toxic than their NAC-counterparts (Dwivedi et al., 2011). 408 
The IC50 of each polymer was also evaluated after allowing the cells a 24 h recovery period in 409 
supplemented EMEM post-treatment with polymers and similar plots of % cell viability 410 
versus log polymer concentrations prepared (figure 4). The IC50 values of each polymer 411 
obtained from MTT assays conducted with a recovery period are displayed in table 2. The 412 
concentration at which a significant (p<0.05) drop in cell viability for each polymer are 413 
displayed in table 3. 414 
The purpose of introducing a recovery period was to determine the extent to which cells 415 
could recover from the effect of the different polymers. This may give more insight on 416 
whether the effect of the polymers on cells are transient/reversible (cytostatic) or permanent 417 
(cytotoxic). Results shown in table 2 indicate that the inclusion of a recovery period before 418 
treating the cells with MTT resulted in an increase in IC50 for all the polymers tested (figure 419 
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5). Indeed all polymers demonstrated a significant (p<0.05) increase in cell viability with a 420 
recovery period (table 4). 421 
QPAA appeared to only show a cytostatic effect as no loss of cell viability was observed (100 422 
% cell viability) between the cencentration 0.001-4 mgml-1 post-recovery. All other polymers 423 
displayed reduced cell viability and thus cytotoxicity, but at higher concentrations than 424 
without a recovery period.  425 
NAC-based thiomers demonstrated a marked improvement (approximately 6-fold) in their 426 
IC50 value after being subjected to a recovery period (figures 4 and 5). The effects of these 427 
polymers on cells appear to have been cytostatic rather than cytotoxic at polymer low 428 
concentrations, as cells were still viable and able to recover on removal of polymer solutions 429 
and their replacement with fresh growth media. Hence this suggests that the effects of these 430 
polymers on cells at low concentrations are largely reversible, and do not result in permanent, 431 
irreparable damage.  432 
On the other hand, polymers PAA and PAA-TBA showed little improvements in their IC50 433 
(about 1.5 fold) with the introduction of a recovery period (figure 5). This indicates that these 434 
polymers have some cytotoxic properties, and their interactions with cells mostly causes 435 
irreparable damage to cells and marked loss in cell viability.  This again confirms the highly 436 
cytotoxic effect of the primary amine groups in PAA  and  suggests the amidine thiol 437 
substructure of PAA-TBA is a relatively cytotoxic moiety although less toxic than primary 438 
amine groups (TBA substitution of PAA improved IC50 both with and/or without a recovery 439 
period as may be seen in table 2 and 3).  Bearing in mind that the difference in level of thiol 440 
substitution between PAA-TBA and PAA-NAC may not allow direct comparison of their 441 
toxic effects on cells,  the presence of a protonable group within the amidine bond as 442 
compared to the uncharged amide bonds of PAA-NAC (refer to figures 1 and 2) could 443 
however result in an increase in potential to cause toxic effects. QPAA-TBA also appeared to 444 
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show cytostatic effects, although IC50 values were lower than QPAA and QPAA-NAC. The 445 
IC50 of QPAA-TBA was improved considerably after the introduction of a recovery period 446 
much higher than what was observed with PAA and PAA-TBA, but to a lesser extent to 447 
QPAA and QPAA-NAC.  448 
Considering the results of the cytotoxicity assays conducted with and/or without a recovery 449 
period the toxicity profile of the parent polymer was found to play a role in determining the 450 
biocompatibility of the thiolated derivatives. For non-quaternised thiomers where the parent 451 
backbone PAA was cytotoxic, the toxicity profile of the polymers followed this order: PAA > 452 
PAA-TBA > PAA-NAC. While for quaternised polymers where the parent backbone QPAA 453 
was found to be less-cytotoxic , the toxicity profile of the thiomers followed this order 454 
QPAA-TBA > QPAA-NAC > QPAA. This may then indicate that when developing PAA-455 
based thiomers, using QPAA as the parent polymer rather than PAA improves the 456 
biocompatibility of the resultant thiomers.   457 
Futher biocompatibility issues to be aware of include the fact that the particulate nature of 458 
PEC delivery system may increase their potential to elicit immune responses in-vivo and 459 
affect its biodistribution/cellular trafficking altering their toxicity profile (Dufes et al., 2004 460 
and Dwivedi et al., 2011). These however are factors to be considered in future work. 461 
 462 
3.3. CELLULAR UPTAKE STUDIES 463 
 464 
3.3.1. Fluorescence microscopy of polymer, insulin PECs  465 
After a 2 h incubation of cells with fluorescent complexes, their uptake into Caco-2 cells was 466 
visualised using separate fluorescent filters (specific for insulin-FITC and RBITC-tagged 467 
polymers) and a FITC/RBITC combination filter to identify areas of polymer, insulin 468 
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colocalisation. Results are shown in figure 6 and are representative of images taken from one 469 
of the replicate wells.  470 
Only complexes prepared using QPAA and QPAA-TBA appear to be internalised by cells 471 
(Figure 6). Polymer, insulin colocalisation was confirmed by the appearance of numerous 472 
light yellow fluorescent spots within the cell layer as may be seen in figure 6A and 6B, 473 
viewed using the RBITC/FITC combination filter. Cellular uptake of other complexes, e.g. 474 
PAA, appeared to be more cell membrane-associated as fluorescence was observed mostly 475 
round the cell membrane area (figure 6D). 476 
Images were also taken of the same region of the cell layer using the different filter sets. The 477 
brightfield image of the cell layer was also imaged after washing with trypan blue to 478 
determine cell viability; the appearance of the blue/black trypan blue stain indicated non-479 
viable cells (figure 7A) were present. Very few cells were stained by trypan blue after 2 h 480 
incubation with QPAA and QPAA-TBA (figures 7 and 8). This would suggest that the uptake 481 
of PECs was not due to cell damage and was due to other uptake mechanisms. 482 
The uptake process of QPAA and QPAA-TBA, insulin PECs was observed to be time-483 
dependent with the cell layer being observed to attain visible intracellular fluorescence (PEC 484 
uptake) between 1-4 h (data not shown). The uptake process was also not affected by PEC 485 
concentration as reducing PEC concentration to 0.005:0063 mgml-1 (polymer:insulin) did not 486 
inhibit the uptake of complexes (data not shown). The effect of increasing the amount of 487 
PAA and non-quaternised complexes used (to match that used for quaternised polymers) 488 
could not be evaluated because of the low IC50 of non-quaternised polymers.  489 
In order to try and confirm the presence of PECs within the cells, the nuclei of Caco-2 cells 490 
were stained with DAPI. For both QPAA and QPAA-TBA complex formulations, distinct 491 
regions of PEC colocalisation with the blue DAPI stain could be observed (as bright spots), 492 
suggesting that these complexes were located within the cell cytoplasm (figure 9). While 493 
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PAA complexes did not appear to be localised under the blue DAPI stain as can be seen in 494 
figure 9A. 495 
The structure of the polymer used in PEC formulation was observed to play a role in 496 
determining the cellular uptake profile of different PECs by Caco-2 cells. Factors that may 497 
affect the ability of the polymer in facilitating PEC uptake include structural composition of 498 
the polymer, charge density, molecular weight, polymer conformation as well as 499 
hydrophilic/lipophilic balance (Fischer et al., 2003, Florence et al., 2000 and Malik et al., 500 
2000).  501 
 502 
3.3.2. Fluorescence microscopy and quantification of polymer uptake 503 
Cellular uptake of RBITC-tagged polymer solutions (same concentrations as used for each 504 
PEC formulation) was also carried out by fluorescence microscopy (figures 10 and 11). 505 
While most quaternised polymers were taken up by cells, non-quaternised polymers were 506 
poorly taken up by Caco-2 cells with the exception of PAA. Quaternisation enhanced the 507 
uptake profile of PAA-NAC and PAA-TBA, confirming the importance of the quaternary 508 
group in promoting cellular uptake. Unlike their PEC formulations, PAA and QPAA-NAC 509 
were also taken up by Caco-2 cells as a shown in figures 10A and 11C. This implies that the 510 
properties of the original polymer may also be altered after complexation with insulin, 511 
resulting in a complex with different physicochemical properties from the parent molecules. 512 
Complexation of PAA and QPAA-NAC with insulin may have limited the ability of charged 513 
sites on these polymers to interact with the cell membrane and initiate uptake of PECs. This 514 
may be due to polymer, insulin complexation rendering charged sites on these polymers 515 
unavailable for interaction with the cell membrane. The PEC network may also create a steric 516 
barrier that prevents sites on the polymer from accessing compatible cell membrane 517 
components thereby limiting uptake (Harris and Chess, 2003). PAA and QPAA-NAC 518 
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polymers however show better uptake than PAA-TBA and PAA-NAC polymers as shown in 519 
figures 10 and 11.  520 
Uptake of RBITC-tagged polymers was also quantified by fluorimetry after solubilising 521 
treated cell layers with 2 % SDS.  This experiment was carried out for PAA, QPAA and 522 
thiolated QPAA. Thiolated PAA solutions were not analysed as their cellular uptake was 523 
observed to be poor. The results are detailed in table 5. 524 
The results of the quantification experiment shown in table 5 are consistent with the results of 525 
fluorescence microscopy, showing that all quaternised polymers were taken up by the cells 526 
and the percentage of quaternised polymers taken up approximately double the amount of 527 
PAA uptake. The analysis was however not done with polymer, insulin complexes due to 528 
difficulties in obtaining a reliable calibration curve for insulin-FITC with the fluorimeter.  529 
(Fluorescence microscopy has shown polymer, insulin colocalisation was evident for QPAA 530 
and QPAA-TBA.) The results of the quantification process also confirm the fluorescence 531 
microscopy results which show cellular uptake of PAA and QPAA-NAC from their polymer 532 
solutions, even though uptake of their insulin PECs appeared to be negligible.  533 
 534 
3.3.3. Identifying mechanisms of cellular uptake of PECs 535 
To clarify the mechanisms involved in the cellular uptake of QPAA and QPAA-TBA PECs 536 
into the cytoplasm, Caco-2 cell layers were pre-incubated for 2 hs in calcium-free EMEM, to 537 
deplete cells of intracellular calcium stores, or incubated with free insulin (3 µgml-1) for 1 h 538 
(to saturate insulin receptors) prior to treatment with QPAA, insulin and QPAA-TBA, insulin 539 
complexes. Cell layers were subsequently examined by fluorescence microscopy to observe 540 
any changes in the uptake profile of the aforementioned complexes (figures 12, 13, 14 and 541 
15).  542 
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Figures 12 and 13 show the uptake of QPAA and QPAA-TBA, insulin PECs in calcium-free 543 
media compared to those from normal uptake conditions (FCS-free supplemented EMEM). 544 
Cells incubated in calcium-free media before treatment with QPAA and QPAA-TBA, insulin 545 
PECs were observed to show uptake similar to the results obtained in normal media, 546 
suggesting that the processes involved in the cellular uptake of both QPAA and QPAA-TBA 547 
insulin PECs appear independent of calcium-based mechanisms.   548 
Pre-saturation of insulin receptors did not affect uptake of QPAA-TBA insulin complexes, 549 
which were still observed to be taken up regardless of the down-regulation of insulin 550 
receptors as shown in figure 14. 551 
The pre-saturation process appeared to have a noticeable effect on the uptake of QPAA, 552 
insulin complexes as figure 15 shows that unlike figure 15A where the interior of the cells 553 
contains fluorescent spots figure 15B shows that uptake of QPAA complexes was affected by 554 
pre-saturating cell insulin receptors. The images taken with the RBITC and FITC filters also 555 
confirm poor uptake of the formulation (figures 15D and 15F, respectively). This suggests 556 
that uptake of QPAA, insulin complexes appears to benefit from interaction of complexed 557 
insulin with receptors on the cells and may also imply that the conformation of QPAA allows 558 
for complexed insulin to be held on or near the surface of the PEC enabling the insulin 559 
molecule adequate interaction with its receptor. Insulin receptors have been found to be 560 
present on the luminal surface of the small intestine (Buts et al., 1997) and several studies 561 
have confirmed active transcytosis of insulin through the intestinal epithelial cells (Bendayan  562 
et al., 1994 and King and Johnson, 1985). This highlights the active role the insulin receptor 563 
may play in the uptake of complexed insulin into the cells. Some reviews have however 564 
stated that for interaction of insulin with its receptor to take place, insulin has to be in its 565 
monomeric state and that insulin hexamer and aggregate formation is promoted by changes in 566 
environmental pH in-vivo (Russell-Jones, 2011). Hence complexation of insulin with QPAA 567 
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which possesses a quaternary group may limit pH-dependent changes of insulin from the 568 
monomeric to the hexameric state enhancing insulin receptor–mediated uptake. The 569 
stabilising effect of polymer-insulin linkage on insulin structure has been previously 570 
documented by other groups.  Linkage of Vit B12 or PEG to the Lys-29 residue of insulin was 571 
reported to inhibit formation of the insulin hexamer, facilitating interaction of the insulin 572 
monomer with insulin receptors on the surface of the epithelial cells and contributing to a 573 
marked increase in the oral insulin bioavailability of these formulations (Petrus et al., 2002 574 
and Still, 2002).  575 
Further work is needed to clarify the exact mechanisms responsible for cellular uptake of 576 
these complexes. This may involve the use of specific inhibitors like sodium azide which 577 
inhibits metabolic processes as well as cytochalasin D and nocodazole, which are inhibitors 578 
of the endocytotic trafficking pathway (Thompson et al., 2011). Hypothesizing on the fate of 579 
the complexes in the cytosol, it is hoped that insulin PEC delivery systems will not only 580 
initiate uptake of the protein, but also facilitate transport of complexes across the cells 581 
(transcytosis). In an attempt to effect and control PEC uptake and transport in biological 582 
systems, future work may be directed at functionalization of PECs using receptor-583 
recognisable ligands to facilitate active receptor-mediated transcytosis as opposed to relying 584 
on passive uptake mechanisms depicted in the present work. This concept is already being 585 
investigated by groups using the vit B12 ligand to produce receptor-mediated transcytosis of 586 
nanoparticles via the vit B12 receptors (Chalasani et al., 2007). 587 
 588 
 589 
 590 
 591 
 592 
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4. CONCLUSION 593 
The biocompatibility of the parent polymer PAA was improved by both thiol and quaternary 594 
substitution, with quaternisation offering a more substantial improvement in biocompatibility 595 
profile than thiolation. Thiolation was observed to lower the IC50 of QPAA, although QPAA, 596 
PAA-NAC and QPAA-NAC appeared to be largely cytostatic rather than cytotoxic. Uptake 597 
of polymer, insulin complexes by Caco-2 cells was observed to be highly dependent on 598 
polymer structure, with QPAA and QPAA-TBA showing the best potential for facilitating 599 
intracellular uptake of complexed insulin. Uptake of QPAA-TBA insulin PECs was found to 600 
be unaffected by down-regulation of insulin receptors and inhibition of calcium-dependent 601 
mechanisms, while cellular uptake of QPAA, insulin PECs was independent of calcium-602 
based mechanisms but affected by down-regulation of insulin receptors. The results obtained 603 
indicate that these PAA-based polymer, insulin PECs specifically QPAA and QPAA-TBA 604 
formulations show considerable potential in promoting the delivery of insulin through the 605 
oral route. 606 
 607 
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Legends to Figures 760 
Fig. 1: Presumptive structure of repeating units of NAC conjugates of a) PAA: PAA-NAC b) 761 
QPAA:QPAA-NAC. 762 
Fig. 2: Presumptive structure of repeating units of thiobutylamidine conjugates of a) PAA: 763 
PAA-TBA b) QPAA:QPAA-TBA. 764 
Fig. 3: Caco-2 cell viability (%) as determined by MTT assay after 24 h exposure to varied 765 
concentrations of PAA, QPAA and their thiolated derivatives without a recovery period (n 766 
=3; ± S.D.). 767 
Fig. 4: Caco-2 cell viability (%) as determined by MTT assay post-24 h recovery period and 768 
24 h exposure to varied concentrations of PAA, QPAA and thiolated derivatives (n =3; ± 769 
S.D.). 770 
Fig. 5: IC50 (mgml-1) of polymers as determined by MTT assay without a recovery period 771 
(WOR) and post-24 h recovery period (WR) (n =3; ± S.D.). Key: WOR-without recovery 772 
period; WR – with recovery period.  773 
Fig. 6: Fluorescent microscopy images of Caco-2 cells treated with A) QPAA, insulin PECs 774 
B) QPAA-TBA, insulin PECs C) QPAA-NAC, insulin PECs D) PAA, insulin PECs E) PAA-775 
TBA, insulin PECs F) PAA-NAC, insulin PECs  viewed using RBITC/FITC combination 776 
filter. Scale bar-50 µm. 777 
Fig. 7: Fluorescent microscopy images of Caco-2 cells treated with QPAA, insulin complexes 778 
viewed using A) brightfield B) RBITC/FITC combination filter C) FITC filter D) RBITC 779 
filter. Scale bar-50 µm. 780 
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Fig. 8: Fluorescent microscopy images of Caco-2 cells treated with QPAA-TBA, insulin 781 
complexes viewed using A) brightfield B) RBITC/FITC combination filter C) FITC filter D) 782 
RBITC filter. Scale bar-50 µm. 783 
Fig. 9: Fluorescent microscopy images of Caco-2 cells treated with PECs and DAPI. A) PAA 784 
PECs on RBITC/FITC combination filter B) QPAA PECs on RBITC/FITC combination filter 785 
C) QPAA-TBA PECs on RBITC/FITC combination filter. Scale bar-50 µm. 786 
Fig. 10: Fluorescent microscopy images of Caco-2 cells treated with A) PAA C) PAA-TBA 787 
D) PAA-NAC; viewed using the RBITC filter. Scale bar-50 µm. 788 
Fig. 11: Fluorescent microscopy images of Caco-2 cells treated with A) QPAA C) QPAA-789 
TBA D) QPAA-NAC viewed using the RBITC filter. Scale bar-50 µm. 790 
Fig. 12: Fluorescent microscopy images of Caco-2 cells post treatment with QPAA, insulin 791 
complexes in A) normal media-RBITC/FITC combination filter  B) calcium-free media-792 
RBITC/FITC combination filter C) normal media-RBITC filter  D) calcium free media-793 
RBITC filter  E) normal media-FITC filter  F) calcium free media-FITC filter. Scale bar-50 794 
µm. 795 
Fig. 13: Fluorescent microscopy images of Caco-2 cells post treatment with QPAA-TBA, 796 
insulin complexes in A) normal media-RBITC/FITC combination filter  B) calcium-free 797 
media-RBITC/FITC combination filter C) normal media-RBITC filter  D) calcium free 798 
media-RBITC filter  E) normal media-FITC filter  F) calcium free media-FITC filter. Scale 799 
bar-50 µm. 800 
Fig. 14: Fluorescent microscopy images of Caco-2 cells treated with QPAA-TBA, insulin 801 
complexes where cell insulin receptors are A) normal-RBITC/FITC combination filter B) 802 
pre-saturated with insulin-RBITC/FITC combination filter C) normal-RBITC filter D) pre-803 
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saturated with insulin-RBITC combination filter E) normal-FITC filter F) pre-saturated with 804 
insulin-FITC combination filter. Scale bar-50 µm. 805 
Fig. 15: Fluorescent microscopy images of Caco-2 cells treated with QPAA, insulin 806 
complexes where cell insulin receptors are A) normal-RBITC/FITC combination filter B) 807 
pre-saturated with insulin-RBITC/FITC combination filter C) normal-RBITC filter D) pre-808 
saturated with insulin-RBITC combination filter E) normal-FITC filter F) pre-saturated with 809 
insulin-FITC combination filter. Scale bar-50 µm. 810 
 811 
 812 
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 814 
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 819 
 820 
 821 
 822 
 823 
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Fig. 1: Presumptive structure of repeating units of NAC conjugates of a) PAA: PAA-NAC b) QPAA:QPAA-NAC. 825 
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Fig. 2: Presumptive structure of repeating units of thiobutylamidine conjugates of a) PAA: PAA-TBA b) QPAA:QPAA-827 
TBA. 828 
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Fig. 3: Caco-2 cell viability (%) as determined by MTT assay after 24 h exposure to varied concentrations of PAA, QPAA 830 
and their thiolated derivatives without a recovery period (n=3; ± S.D.). 831 
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Fig. 4: Caco-2 cell viability (%) as determined by MTT assay post-24 h recovery period and 24 h exposure to varied 835 
concentrations of PAA, QPAA and thiolated derivatives (n=3; ± S.D.). 836 
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1Results obtained from the MTT assay of QPAA with a recovery period indicated that the IC50 of the polymer was higher 842 
than the highest polymer concentration tested (4 mgml-1). 843 
Fig. 5: IC50 (mgml-1) of polymers as determined by MTT assay without a recovery period (WOR) and post-24 h recovery 844 
period (WR) (n =3; ± S.D.). Key: WOR-without recovery period; WR – with recovery period.  845 
 846 
Fig. 6: Fluorescent microscopy images of Caco-2 cells treated with A) QPAA, insulin PECS B) QPAA-TBA, insulin PECS 847 
C) QPAA-NAC, insulin PECS D) PAA, insulin PECS E) PAA-TBA, insulin PECS F) PAA-NAC, insulin PECS  viewed 848 
using RBITC/FITC combination filter. Scale bar-50 µm. 849 
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Fig. 7: Fluorescent microscopy images of Caco-2 cells treated with QPAA, insulin complexes viewed using A) brightfield 851 
B) RBITC/FITC combination filter C) FITC filter D) RBITC filter. Scale bar-50 µm. 852 
  853 
Fig. 8: Fluorescent microscopy images of Caco-2 cells treated with QPAA-TBA, insulin complexes viewed using A) 854 
brightfield B) RBITC/FITC combination filter C) FITC filter D) RBITC filter. Scale bar-50 µm. 855 
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Fig. 9: Fluorescent microscopy images of Caco-2 cells treated with PECS and DAPI. A) PAA PECS on RBITC/FITC 857 
combination filter B) QPAA PECS on RBITC/FITC combination filter C) QPAA-TBA PECS on RBITC/FITC combination 858 
filter. Scale bar-50 µm. 859 
 860 
Fig. 10: Fluorescent microscopy images of Caco-2 cells treated with A) PAA C) PAA-TBA D) PAA-NAC; viewed using the 861 
RBITC filter. Scale bar-50 µm. 862 
 863 
Fig. 11: Fluorescent microscopy images of Caco-2 cells treated with A) QPAA C) QPAA-TBA D) QPAA-NAC viewed 864 
using the RBITC filter. Scale bar-50 µm. 865 
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Fig. 12: Fluorescent microscopy images of Caco-2 cells post treatment with QPAA, insulin complexes in A) normal media-867 
RBITC/FITC combination filter  B) calcium-free media-RBITC/FITC combination filter C) normal media-RBITC filter  D) 868 
calcium free media-RBITC filter  E) normal media-FITC filter  F) calcium free media-FITC filter. Scale bar-50 µm. 869 
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Fig. 13: Fluorescent microscopy images of Caco-2 cells post treatment with QPAA-TBA, insulin complexes in A) normal 872 
media-RBITC/FITC combination filter  B) calcium-free media-RBITC/FITC combination filter C) normal media-RBITC 873 
filter  D) calcium free media-RBITC filter  E) normal media-FITC filter  F) calcium free media-FITC filter. Scale bar-50 874 
µm. 875 
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 876 
Fig. 14: Fluorescent microscopy images of Caco-2 cells treated with QPAA-TBA, insulin complexes where cell insulin 877 
receptors are A) normal-RBITC/FITC combination filter B) pre-saturated with insulin-RBITC/FITC combination filter C) 878 
normal-RBITC filter D) pre-saturated with insulin-RBITC combination filter E) normal-FITC filter F) pre-saturated with 879 
insulin-FITC combination filter. Scale bar-50 µm. 880 
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Fig. 15: Fluorescent microscopy images of Caco-2 cells treated with QPAA, insulin complexes where cell insulin receptors 882 
are A) normal-RBITC/FITC combination filter B) pre-saturated with insulin-RBITC/FITC combination filter C) normal-883 
RBITC filter D) pre-saturated with insulin-RBITC combination filter E) normal-FITC filter F) pre-saturated with insulin-884 
FITC combination filter. Scale bar-50 µm. 885 
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 888 
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Table 1: Free thiol content, disulphide bond content, total thiol content and zeta potential of polymers. Values are mean ± S.D. (n = 3). 891 
Polymer 
Free thiol content 
(µmolg-1) 
S-S bond content 
(µmolg-1) 
Total thiol substitution 
(µmolg-1) 
Zeta Potential (mV) 
PAA n/a n/a n/a 41.9 ± 2 
QPAA n/a n/a n/a 45.0 ± 3 
PAA-NAC 60 ± 1.2 280 340 ± 4.1 35.7 ± 1 
QPAA-NAC 60 ± 4.3 220 280 ± 3.3 37.4 ± 1 
PAA-TBA 490 ± 18 590 1080 ± 28 46.9 ± 1 
QPAA-TBA 440 ± 21 560 1000 ± 31 48.4 ± 1 
 892 
 893 
 894 
 895 
 896 
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Table 2: IC50 values (mgml-1) of PAA, QPAA and thiolated derivatives obtained without/with a 24 h recovery period. Values are mean ± S.D. (n 897 
= 3). 898 
 PAA QPAA PAA-NAC QPAA-NAC PAA-TBA QPAA-TBA 
Without 
Recovery 
Period 
0.009 ± 0.003 0.062 ± 0.001 0.011 ± 0.009 0.036 ± 0.003 0.023 ± 0.002 0.024 ± 0.003 
With 
Recovery 
Period 
0.013 ± 0.005 >4 0.064 ± 0.002 0.144 ± 0.007 0.033 ± 0.009 0.110 ± 0.003 
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Table 3: Concentration of polymer at which a significant (p<0.05) drop of cell viability is observed when compared to the respective vehicle 905 
control. 906 
 Paa QPaa Paa-NAC QPaa-NAC Paa-TBA QPaa-TBA 
Without 
Recovery 
Period 
0.02 0.08 0.02 0.08 0.03 0.05 
With 
Recovery 
Period 
0.03 NA 0.1 0.1 0.03 1.0 
 907 
 908 
 909 
 910 
 911 
 912 
 913 
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Table 4: Level of significant difference in cell viability with vehicle control for each of the polymers at each of the concentrations tested (n=3). 914 
Polymer 
concentration 
(mg/ml) 
PAA PAA-NAC PAA-TBA QPAA QPAA-NAC QPAA-TBA 
Without 
Recovery 
Period 
With 
Recovery 
Period 
Without 
Recovery 
Period 
With 
Recovery 
Period 
Without 
Recovery 
Period 
With 
Recovery 
Period 
Without 
Recovery 
Period 
With 
Recovery 
Period 
Without 
Recovery 
Period 
With 
Recovery 
Period 
Without 
Recovery 
Period 
With 
Recovery 
Period 
1 NS NS NS NS NS NS NS NS NS NS NS NS 
5 NS NS NS NS NS NS NS NS NS NS NS NS 
8 NS NS NS NS NS NS NS NS NS NS NS NS 
10 NS NS NS NS NS NS NS NS NS NS NS NS 
20 *** NS * NS NS NS NS NS NS NS NS NS 
30 *** * *** NS ** NS NS NS NS NS NS NS 
40 *** *** *** NS ** * NS NS NS NS NS NS 
50 *** *** *** NS * * NS NS NS NS ** NS 
80 *** *** *** NS *** ** NS NS * NS * NS 
100 *** *** *** ** *** *** * NS * * ** NS 
1000 *** *** *** *** *** *** *** NS *** ** *** *** 
Key: NR = NO RECOVERY PERIOD; R = RECOVERY PERIOD; NS = NOT SIGNIFICANT I.E. P>0.05; *= P<0.05; ** = P<0.01; 915 
*** = P<0.001. 916 
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Table 5: Percentage uptake of incubated polymer mass by Caco-2 cells. Values are mean ± S.D. (n=3). 917 
 PAA QPAA QPAA-NAC QPAA-TBA 
% Polymer uptake 12.55 ± 0.83 22.88 ± 1.77 26.48 ± 1.40 28.50 ±  0.38 
 918 
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 924 
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